GLP1R and hydrops fetalis: For patients with clinical CVD, an SGLT2 inhibitor or a GLP-1 receptor agonist with proven cardiovascular benefit is recommended while for those patients with CKD or HF and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended.